BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million [Reuters]
Haemonetics Corporation (HAE)
Last haemonetics corporation earnings: 2/4 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome
Company Research
Source: Reuters
BRIEF-Haemonetics Corp Qtrly Revenue $234.0 Million | Reuters Reuters Staff 2 Min Read Feb 6 (Reuters) - Haemonetics Corp: * QTRLY ADJUSTED EARNINGS PER SHARE $0.62; QTRLY LOSS PER SHARE $0.12 * BOARD OF DIRECTORS AUTHORIZES $260 MILLION SHARE REPURCHASE PROGRAM? * INCURRED $31.3 MILLION OF RESTRUCTURING AND TURNAROUND COSTS IN QUARTER * SEES FISCAL 2018 ADJUSTED EARNINGS PER SHARE $1.80 - $1.90 * SEES FISCAL 2018 FREE CASH FLOW, BEFORE RESTRUCTURING & TURNAROUND OF ABOUT $125 MILLION * HAEMONETICS- COMPLEXITY REDUCTION INITIATIVE EXPECTED TO DELIVER $80 MILLION IN ANNUAL RUN RATE SAVINGS; SAVINGS ARE EXPECTED TO BE MINIMAL IN FISCAL 2018 * Q3 EARNINGS PER SHARE VIEW $0.44, REVENUE VIEW $227.6 MILLION -- THOMSON REUTERS I/B/E/S * EXPECTS TO INCUR AGGREGATE RESTRUCTURING CHARGES OF $50-$60 MILLION TO COMPLETE COMPLEXITY REDUCTION INITIATIVE * FY2018 EARNINGS PER SHARE VIEW $1.70 -- THOMSON REUTERS I/B/E/S Source text for Eikon: ( bit.ly/2FRec83 ) Further company coverage: All quotes d
Show less
Read more
Impact Snapshot
Event Time:
HAE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HAE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HAE alerts
High impacting Haemonetics Corporation news events
Weekly update
A roundup of the hottest topics
HAE
News
- Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $105.00 price target on the stock.MarketBeat
- Why You Should Add Haemonetics (HAE) to Your Portfolio Now [Yahoo! Finance]Yahoo! Finance
- Apheresis Market Worth $3.9 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024 [Yahoo! Finance]Yahoo! Finance
- Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024PR Newswire
HAE
Earnings
- 2/8/24 - Beat
HAE
Sec Filings
- 4/17/24 - Form 4
- 4/1/24 - Form 8-K
- 3/13/24 - Form 4
- HAE's page on the SEC website